Incredible

Exploiting the tumor microenvironment in novel ways

Tumor microenvironment modulated prodrugs combine strong potency with great tolerability.

Convert Pharmaceuticals develops prodrugs that are inert upon administration to patients, but transform into potent anti-cancer agents upon entering tumors. Convert’s proprietary insights in both the tumor microenvironment and specific biomarkers as well as the chemical design of prodrugs guide the development of these next-generation therapeutics.

Convert Pharmaceuticals - Hypoxia-Activated Prodrugs

Latest news

  • 12
    Feb

    Convert Pharmaceuticals, a Belgian biotech company developing anti-cancer therapeutics, has obtained very promising pre-clinical results with CP-506 drug, a new and improved Hypoxia Activated Prodrug. The company is finalising its Clinical Trial Application to obtain regulatory approval for the launch of its tumor agnostic Phase......